RET and non-small cell lung carcinoma: In fact, based on the population PK model for pralsetinib, which included 491 subjects (193 healthy subjects, 161 patients with NSCLC, 124 patients with RET-mutation positive MTC and 13 patients with RET-fusion positive thyroid) with 7566 quantifiable pralsetinib concentrations pooled from 5 clinical studies, the PK of pralsetinib was characterized by a one-compartment model with linear elimination [3,14].